Physician profile
Kami Choy
NPI 1912492315
$7,724.41
in general payments reported to CMS, 2019-2025
23 companies · $542 in 2025
The $542 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,253 · 2020: $378 · 2021: $26.91 · 2022: $102 · 2023: $1,171 · 2024: $2,251 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017 · Travel and Lodging: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.17 |
| Travel and Lodging | $946.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,343.68 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $1,802.40 | 2023-2024 | Miebo, Xiidra, Infuse |
| Coopervision INC. | $696.39 | 2019-2025 | Misight Contact Lens |
| Biotissue Holdings INC. | $447.99 | 2022-2024 | |
| Alcon Vision LLC | $308.04 | 2023-2025 | Total30, Dailies Total1, Precision 1 |
| Amgen INC. | $279.67 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $254.35 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $243.99 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $181.28 | 2019-2020 | |
| Abb Con-Cise Optical Group LLC | $147.43 | 2019 | |
| Optos, INC. | $140.49 | 2020 | |
| Apellis Pharmaceuticals, INC. | $127.09 | 2024 | Syfovre |
| Abbvie INC. | $124.99 | 2023 | Vuity |
| Aerie Pharmaceuticals, INC. | $123.35 | 2019 | |
| Sun Pharmaceutical Industries INC. | $122.07 | 2023 | Cequa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $121.85 | 2023 | Izervay |
| Allergan, INC. | $87.26 | 2019 | |
| Shire North American Group INC | $61.54 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.93 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $15.06 | 2019 | |
| Tearlab Corp | $13.95 | 2019 | |
| Visioneering Technologies, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kami Choy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.